Option chain shows key data for RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD.'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD..

RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD. (OTC:RBGGF) Stock, Option Chain

RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD.

WIIM

BCTX

BriaCell Therapeutics shares are trading higher after the company announced it dosed the first patient in its Phase 1/2 study of Bria-OTS.

KKR shares are trading higher after the company announced n approximately $370 million growth investment in Lighthouse.

Raymond James analyst Brian Gesuale initiates coverage on Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) with a Outperform rating and announces Price Target of $30.

News

Price Target

Initiation

Analyst Ratings

AMTM

Raymond James Initiates Coverage On Amentum Holdings with Outperform Rating, Announces Price Target of $30

Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is evaluating options for its Chinese operations, including the potential sale of a stake in the business.
The coffee chain has consulted advisers on strategies to expand in China and has gauged interest from potential investors, including local private equity firms, Bloomberg cites familiar <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-21/starbucks-is-said-to-consider-selling-stake-in-chinese-business?sref=TBDibEcD" rel="noreferrer noopener">sources</a>. Possible buyers include Chinese conglomerates or regional companies with relevant industry expertise.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42109965/baidus-q3-earnings-revenue-slides-weak-online-ads-market-impact-margins" rel="noreferrer noopener">Baidu&#8217;s Q3 Earnings: Revenue Slides, Weak Online Ads Market Impact Margins</a>
Starbucks is seeking strategic partnerships in China as it grapples with declining sales in the region. Once its fastest-growing market, China now faces economic headwinds, including a property slump, employment uncertainties, and slower consumer spending, SCMP <a target="_blank" href="https://www.scmp.com/business/companies/article/3287574/starbucks-seeks-strategic-partnership-find-perk-china-amid-brewing-price-war?module=perpetual_scroll_0&amp;pgtype=article" rel="noreferrer noopener">reports</a>.
The company faces mounting pressure from activist investor Elliott Investment Management, which has urged a review of its Chinese business. Other Western brands have made similar moves, such as McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) and Yum! Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), which sold stakes in their Chinese operations to private equity investors to drive growth and adapt to local market demands.
China, Starbucks&#8217; second-largest market, generated approximately $3 billion in revenue last year, with the store count increasing by 12%. Despite this growth, Starbucks is contending with stiff competition from local rivals like Luckin Coffee Inc, which has rapidly gained market share with more affordable offerings.
Starbucks saw its same-store sales in China shrink by 14% in the fiscal fourth quarter ending September, surpassing its global sales decline of 9%.
Rising competition from cost-effective rivals such as Luckin Coffee and Cotti Coffee has further strained its position, as these companies attract budget-conscious consumers with significantly lower-priced offerings.
Brian Niccol, who became CEO in August 2024, acknowledged the challenges, citing an &#8220;extreme&#8221; competitive environment and macroeconomic pressures.
Starbucks&#8217; signature 27-yuan ($3.70) Americano is losing traction against Luckin Coffee&#8217;s brews, priced at 11.9 yuan, and Cotti Coffee&#8217;s offerings, which initially cost 9.9 yuan before a modest price hike to reduce cash burn.
Cotti Coffee, founded by two former Luckin executives in 2022, has rapidly expanded to 10,000 locations across 28 markets, creating intense competition in China&#8217;s coffee industry.
Meanwhile, Starbucks operated 7,596 stores in China as of September, accounting for 19% of its global footprint.
Starbucks is also contending with the growing popularity of fruit-infused teas and juices, which is increasing competition for consumer spending.
In October, TD Cowen analyst Andrew M. Charles <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41661427/starbucks-faces-sales-slump-but-analysts-see-silver-lining-with-new-ceos-efficiency" rel="noreferrer noopener">reiterated a Buy rating</a> on Starbucks with a price target of $110, emphasizing its potential for over 5% same-store sales growth in North America but noted delays in menu innovation due to SKU simplification efforts.
Wedbush analyst Nick Setyan maintained a Neutral rating for Starbucks but reduced the price target to $95, citing limited near-term visibility on revenue and earnings. Setyan highlighted CEO Brian Niccol&#8217;s focus on reducing wait times to under four minutes while maintaining the coffeehouse experience as a critical improvement. The company plans to eliminate alternative dairy upcharges, impacting U.S. margins by 1%, and will reduce promotional offers, prioritizing marketing efforts and store remodels.
Price Action: SBUX stock is up 1.57% at $99.80 at last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Photo via Shutterstock

Asset Sales

Media

SBUX

Starbucks Eyes Stake Sale in China Amid Fierce Competition and Falling Sales

Piedmont Lithium shares are trading higher after Macquarie upgraded the stock from Underperform to Neutral and announced a price target of $13.5.

TD Cowen analyst Oliver Chen maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Hold and lowers the price target from $165 to $145.

TD Cowen Maintains Hold on Target, Lowers Price Target to $145

SURG

SurgePays shares are trading higher after announcing an agreement with AT&T that enables the company to offer mobile wireless, voice, data, and messaging services.

SurgePays, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares are trading higher after the company inked a deal with AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) to provide mobile wireless, voice, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42110967/surgepays-establishes-strategic-agreement-with-at-t" rel="noreferrer noopener">data, and messaging services</a>.
As per a multi-year mobile virtual network operator (MVNO) agreement, SurgePays will offer its customers reliable 4G LTE and 5G services using AT&amp;T&#8217;s wireless network, which covers over 99% of Americans in North America.
The AT&amp;T agreement enables SurgePays to empower other businesses to deliver MVNO wireless services while expanding into underserved and rural markets. Leveraging its vast network of convenience stores, bodegas, and neighborhood locations, SurgePays ensures easy access to prepaid wireless and financial products.
Brian Cox, Chairman and CEO, said, &#8220;Once service integration with AT&amp;T is complete, we will be able to provide services on a network that our customers can depend on to stay securely connected, whether they are existing SurgePays customers or new ones coming to us through our convenience store distribution channel, operation centers or online.&#8221;
&#8220;Back in July, we announced the hiring and appointment of&nbsp;Joseph Gomez&nbsp;as vice president of MVNO Operations,&#8221; added Cox. &#8220;Joe had served AT&amp;T for decades leading strategic initiatives, developing partnerships and overseeing national sales and distribution channels. He has wasted no time in following through on his charge of driving our MVNO strategy with a focus on market share growth.&#8221;
Price Action: SURG shares are up 17.1% at $1.71 at the last check Thursday.
Image sourced from Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42116183" target="_blank" rel="noreferrer noopener">Michael Saylor Predicted Bitcoin To Hit $13 Million — If It Happens, It Will Entail &#8216;Massive Hyperinflation,&#8217; Analyst Warns</a></li>
</ul>

Equities

Contracts

Small Cap

Movers

SurgePays Teams Up With AT&T For Affordable Wireless Solutions Nationwide; Stock Gains

At the <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California</a> event in Anaheim, Lisa Weser, founder and CEO of Trailblaze, addressed a core debate within the cannabis industry: balancing consumer-driven product trends with a commitment to quality production. 
Weser, alongside other industry professionals, shared insights on how cannabis brands can adapt to shifting consumer preferences while remaining true to high production standards.
<h3 class="wp-block-heading">Consumer Demand or Industry Direction?</h3>
Weser's panel tackled a foundational question: are consumer preferences driving changes in the cannabis industry, or is the industry itself setting expectations? Speaking with experts from Papa &amp; Barkley, Jetty Extracts, Natura, and Timeless Vapes, Weser observed that perspectives on this issue vary widely.
See Also: <a href="https://www.benzinga.com/news/events/24/11/42115223/tax-woes-hemp-rules-california-cannabis-authority-nicole-elliott">From Tax Woes To Hemp Rules: Department Of Cannabis Control&#8217;s Nicole Elliott Outlines Regulatory Goals</a>
One common theme in the discussion was the need to "meet consumers where they are," a concept familiar in the consumer goods space. This approach focuses on crafting products that appeal directly to consumers' tastes. 
"We're seeing new consumers, especially younger ones, drawn to products with bold flavors," Weser said, noting the appeal of flavor-centric offerings over traditional high-grade cannabis flowers for some segments of the market.
<h3 class="wp-block-heading">Back to Basics: Quality First</h3>
In contrast, other panelists argued for a renewed focus on quality in cannabis production. They expressed concern that while consumer trends are essential, some brands may have strayed too far from the core values of cultivating excellent cannabis. According to Weser, many industry leaders believe that true product quality "starts at the farm," emphasizing that the cannabis industry should prioritize strong cultivation practices rather than relying solely on novelty.
This quality-focused viewpoint suggests that long-term success may be achieved by building on reliable practices, producing products that satisfy discerning customers, and reinforcing brand integrity.
<h3 class="wp-block-heading">Striking a Balance</h3>
Weser highlighted that both approaches hold weight in today's diverse cannabis market. Flavor-driven products may help engage newer consumers while focusing on quality that resonates with established users. "Both approaches are valid in today's market," she remarked, underscoring the importance of accommodating the varied needs of cannabis consumers.
This dialogue reflects a larger conversation in the cannabis industry about balancing the drive to meet consumer preferences with a dedication to sustainable quality. By exploring these perspectives, Weser's panel provided valuable takeaways on how brands can connect with different customer bases while maintaining high standards.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111795/californias-cannabis-future-why-one-expert-believes-the-market-will-hold-strong" target="_blank" rel="noreferrer noopener">California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong</a></li>
</ul>
Image: AI-Generated Image

Cannabis

Events

Exclusives

Interview

'Innovation Starts At The Farm': How Cannabis Brands Balance Quality With Consumer Demand

GE Vernova shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a $385 price target.

AMZN

Amazon shares are trading lower following a report suggesting the company is likely to be investigated under the EU's Digital Markets Act next year.

The Container Store shares are trading lower after the company announced it expects the conditions of the sales and purchase agreement (SPA) with Beyond Inc to remain unsatisfied.

Mizuho analyst Gregg Moskowitz maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $165 to $195.

SNOW

Mizuho Maintains Outperform on Snowflake, Raises Price Target to $195

Financial giants have made a conspicuous bullish move on EHang Holdings. Our analysis of options history for EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) revealed 48 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 46 were puts, with a value of $8,928,901, and 2 were calls, valued at $137,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $16.0 for EHang Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in EHang Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to EHang Holdings's substantial trades, within a strike price spectrum from $7.0 to $16.0 over the preceding 30 days.
<h3>EHang Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732207214_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$16.00</td>
<td>$410.0K</td>
<td>1.7K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$16.00</td>
<td>$410.0K</td>
<td>1.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.2</td>
<td>$3.9</td>
<td>$3.96</td>
<td>$16.00</td>
<td>$376.8K</td>
<td>1.7K</td>
<td>5.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$16.00</td>
<td>$350.0K</td>
<td>17.8K</td>
<td>5.4K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$16.00</td>
<td>$349.6K</td>
<td>1.7K</td>
<td>8.3K</td>
</tr>
</tbody>
</table>

<h3>About EHang Holdings</h3>
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
<h3>Where Is EHang Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,647,963, the EH's price is down by -11.91%, now at $13.46. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 113 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for EHang Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

EHang Holdings Unusual Options Activity

TD Cowen analyst Max Rakhlenko maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Buy and raises the price target from $165 to $195.

TD Cowen Maintains Buy on Williams-Sonoma, Raises Price Target to $195

Mizuho analyst Anthony Crowdell maintains AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) with a Outperform and lowers the price target from $24 to $16.

Mizuho Maintains Outperform on AES, Lowers Price Target to $16

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental biologics license application for Andexxa (coagulation factor Xa (recombinant), inactivated -zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening <a href="https://www.benzinga.com/general/health-care">or uncontrolled bleeding.</a>
The FDA initially granted accelerated approval of <a href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-november-21-2024-meeting-announcement-11212024">Andexxa</a>, a recombinant modified human factor Xa (FXa) protein, in 2018 based on the change from baseline in anti-activated FXa (anti-FXa) activity, as a surrogate endpoint reasonably likely to predict clinical benefit as provided for in 21 CFR 601.41.
AstraZeneca was required to conduct a randomized controlled trial to verify and describe the clinical benefit of Andexxa, due to uncertainty as to the relation of the surrogate endpoint to clinical benefit and the observed clinical benefit to ultimate outcomes in the indicated population. In January 2024, the company submitted a supplemental Biologics Licensing Application for Andexxa with the results of the ANNEXA-I trial to fulfill this requirement.
Before the meeting, the FDA panel released <a target="_blank" href="https://www.fda.gov/media/183674/download" rel="noreferrer noopener">brief</a> documents highlighting some safety issues and other concerns.
"Although andexanet showed superiority of the primary efficacy endpoint over UC [usual care] within the PEP [primary efficacy population], the superior efficacy at 12 hours did not predict longer-term benefit," FDA said.
The major safety findings included a doubling of the rate of thromboses and thrombosis-related deaths at Day 30 in the andexanet arm compared with UC.
The major topics for discussion:
<ul>
<li>ANNEXA-I demonstrated an increased incidence of thrombosis (14.6% versus 6.9%) and thrombosis-related deaths at Day 30 (2.5% versus 0.9%) in the andexanet arm compared with the UC arm, respectively. These findings raise concerns regarding whether the serious risks of treatment with andexanet are acceptable in the indicated population.</li>
<li>While the primary efficacy endpoint in ANNEXA-I was met, the treatment difference across arms appears to be primarily driven by one of three components of the composite endpoint, namely the volume of hematoma at 12 hours, while other clinically meaningful endpoints were not different between the two arms. These findings raise the question as to whether the benefit demonstrated in ANNEXA-I outweighs the serious risks.</li>
</ul>
The document highlighted, &#8220;Treatment with andexanet demonstrated a statistically significant improvement in hemostasis compared to UC (andexanet: 65.7% versus UC: 53%). The observed treatment difference between arms appears to be primarily driven by hematoma volume, with more patients in the andexanet arm than UC arm experiencing a ≤35% increase from baseline in hematoma volume at 12 hours (74% versus 60%).&#8221;
Hematoma is a blood collection that pools outside blood vessels, usually caused by an injury or surgery.
Price Action: AZN stock is up 0.97% at $63.82 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42110605/deere-q4-earnings-beats-expectations-steep-sales-drop-margins-squeeze-more" target="_blank" rel="noreferrer noopener">Deere Q4 Earnings: Beats Expectations, Steep Sales Drop, Margins Squeeze &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Biotech

Large Cap

Health Care

General

AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns

SWVL

Swvl Holdings shares are trading higher after the company announced it signed a three-year contract with G4S in Saudi Arabia to provide SaaS-based mobility solutions.

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and raises the price target from $165 to $175.

NVDA

Mizuho Maintains Outperform on NVIDIA, Raises Price Target to $175

<a href="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer" title="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer">https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer</a>

Comments

RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD.

RIMBACO GROUP GLOBAL LTD by RIMBACO GROUP GLOBAL LTD. (RBGGF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga